Straits Times Index
3,292.93 -3.96 (-0.12%) Nikkei
38,236.07 -37.98 (-0.10%) Hang Seng
18,475.92 +268.79 (+1.48%) FTSE 100
8,213.49 +41.34 (+0.51%) Bitcoin USD
63,552.64 +1,763.37 (+2.85%) CMC Crypto 200
1,359.39 +82.41 (+6.45%)
NVO Jan 2026 67.500 call
| Previous close | 69.17 |
| Open | 69.17 |
| Bid | 63.75 |
| Ask | 66.15 |
| Strike | 67.50 |
| Expiry date | 2026-01-16 |
| Day's range | 69.17 - 69.17 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
Yahoo FinanceAmgen's peek at its GLP-1 drug trial results heightens competition in obesity market
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Insider MonkeyNovo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript
Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript May 2, 2024 Novo Nordisk A/S misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.77. NVO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day! And thank […]
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
Bagsværd, Denmark, 3 May 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the
